Mitsui Chemicals Invests in US Biotech Startup iOrganBio

• Mitsui Chemicals invested in US biotechnology startup iOrganBio through its corporate venture capital fund, 321Catalyst.
• The investment supports collaboration to improve human cell and organoid production for drug discovery and regenerative medicine.
• The partners will explore joint development of drug-testing technologies that could complement or replace animal testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mitsui Chemicals Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.